Skyline Medical to Present at Dawson James Securities 3rd Annual Small Cap Growth Conference
October 12 2017 - 8:30AM
Skyline Medical Inc. (NASDAQ:SKLN) (“Skyline” or “the Company”),
producer of the FDA-approved STREAMWAY® System for automated,
direct-to-drain medical fluid disposal, today announced that
management will present at the Dawson James Securities 3rd Annual
Small Cap Growth Conference on Thursday, October 19, 2017 at 3:30
p.m. Eastern time. The conference will be held at the Wyndham Grand
Hotel in Jupiter, Florida on October 18-19, 2017.
To listen to the presentation live, investors
may visit the investor relations section of Skyline Medical’s
website at www.skylinemedical.com. An archived webcast of the
presentation will also be available on the Company’s website for a
period of time.
About Skyline Medical
Skyline Medical produces a fully automated,
patented, FDA-cleared waste fluid disposal system that virtually
eliminates staff exposure to blood, irrigation fluid and other
potentially infectious fluids found in the healthcare environment.
Antiquated manual fluid handling methods that require hand carrying
and emptying filled fluid canisters present an exposure risk and
potential liability. Skyline Medical's STREAMWAY System fully
automates the collection, measurement and disposal of waste fluids
and is designed to: 1) reduce overhead costs to hospitals and
surgical centers; 2) improve compliance with OSHA and other
regulatory agency safety guidelines; 3) improve efficiency in the
operating room, and radiology and endoscopy departments, thereby
leading to greater profitability; and 4) provide greater
environmental stewardship by helping to eliminate the approximately
50 million potentially disease-infected canisters that go into
landfills each year in the U.S. For additional information,
please visit www.skylinemedical.com.
Forward-looking Statements
Certain of the matters discussed in this
announcement contain forward-looking statements that involve
material risks to and uncertainties in the Company's business that
may cause actual results to differ materially from those
anticipated by the statements made herein. Such risks and
uncertainties include , risks related to the proposed merger,
including the fact that we may not complete the merger; we do not
have complete information about CytoBioscience, including audited
financial statements; the combined company will not be able to
continue operating without additional financing; possible failure
to realize anticipated benefits of the merger; costs associated
with the merger may be higher than expected; the merger may result
in disruption of the Company’s and CytoBioscience’s existing
businesses, distraction of management and diversion of resources;
delay in completion of the merger may significantly reduce the
expected benefits; and the market price of the Company’s common
stock may decline as a result of the merger. Other risks and
uncertainties relating to the Company include, among other things,
current negative operating cash flows and a need for additional
funding to finance our operating plan; the terms of any further
financing, which may be highly dilutive and may include onerous
terms; unexpected costs and operating deficits, and lower than
expected sales and revenues; uncertain willingness and ability of
customers to adopt new technologies and other factors that may
affect further market acceptance, if our product is not accepted by
our potential customers, it is unlikely that we will ever become
profitable; adverse economic conditions; adverse results of any
legal proceedings; the volatility of our operating results and
financial condition; inability to attract or retain qualified
senior management personnel, including sales and marketing
personnel; our ability to establish and maintain the proprietary
nature of our technology through the patent process, as well as our
ability to possibly license from others patents and patent
applications necessary to develop products; the Company's ability
to implement its long range business plan for various applications
of its technology; the Company's ability to enter into agreements
with any necessary marketing and/or distribution partners; the
impact of competition, the obtaining and maintenance of any
necessary regulatory clearances applicable to applications of the
Company's technology; and management of growth and other risks and
uncertainties that may be detailed from time to time in the
Company's reports filed with the Securities and Exchange
Commission, which are available for review at www.sec.gov.
This is not a solicitation to buy or sell securities and does not
purport to be an analysis of the Company's financial position. See
the Company's most recent Annual Report on Form 10-K, and
subsequent reports and other filings at www.sec.gov.
Contacts:
Skyline MedicalCarl Schwartz, Chief Executive
Officer(651) 389-4800cschwartz@skylinemedical.com
InvestorsLHA Investor RelationsKim Sutton
Golodetz(212) 838-3777kgolodetz@lhai.com
Precision Therapeutics Inc. (NASDAQ:AIPT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Precision Therapeutics Inc. (NASDAQ:AIPT)
Historical Stock Chart
From Sep 2023 to Sep 2024